Speculative M&A Transaction Analysis, page-781

Time will tell mate. The drugs capability is way low on my list of concerns - but until someone comes knocking with their chequebook out you could have the most capable drug in the world, but hows it going to get into patient's on a global scale? I am invested for deeply personal reasons, I would much rather have bisantrene commercialised sooner and potentially make a little less money in the process than be greedy trying to maximise my own profits. There are more important things in life than money. Sure licensing is a play aswell, as I said we will just have to see what direction the company takes as we progress.

However I stand by my comment, a bird in the hand is worth two in the bush. Each to their own, but a lot of large numbers get thrown around here with such conviction which don’t seem to put much emphasis on the fact that none of it is guaranteed regardless of the drugs progress. They will argue that’s obvious but some people take things here at face value instead of researching them selves. The point I’m making overall is do what’s right for you not someone else just because they say so.

Some might want to take the easy option and throw sledges at me because I don’t agree with them but that says more about them than it does me. All the best with your investing journey.